Aquilo Capital Management, LLC Pro Qr Therapeutics N.V. Transaction History

Aquilo Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$3.58 - $4.85 $8.17 Million - $11.1 Million	-2,281,966 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.79 - $6.3 $572,903 - $753,505	-119,604 Reduced 4.98%	2,281,966 $10.9 Million
Q1 2020 May 15, 2020	BUY	$5.25 - $9.9 $2.51 Million - $4.74 Million	479,000 Added 24.91%	2,401,570 $13.2 Million
Q4 2019 Feb 14, 2020	BUY	$5.84 - $10.51 $6.37 Million - $11.5 Million	1,090,909 Added 131.17%	1,922,570 $19.1 Million
Q3 2019 Nov 14, 2019	BUY	$5.76 - $9.44 $476,928 - $781,632	82,800 Added 11.06%	831,661 $4.79 Million
Q2 2019 Aug 14, 2019	BUY	$9.1 - $15.55 $6.81 Million - $11.6 Million	748,861 New	748,861 $6.82 Million

45.1M

31.4K

24.7K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $166M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Aquilo Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Aquilo Capital Management, LLC with notifications on news.